CN116063387B - Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof - Google Patents

Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof Download PDF

Info

Publication number
CN116063387B
CN116063387B CN202210818325.5A CN202210818325A CN116063387B CN 116063387 B CN116063387 B CN 116063387B CN 202210818325 A CN202210818325 A CN 202210818325A CN 116063387 B CN116063387 B CN 116063387B
Authority
CN
China
Prior art keywords
enzymolysis
peptide
wprp5
antibacterial peptide
antibacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210818325.5A
Other languages
Chinese (zh)
Other versions
CN116063387A (en
Inventor
王家俊
徐浩然
吴万鹏
单安山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeast Agricultural University
Original Assignee
Northeast Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeast Agricultural University filed Critical Northeast Agricultural University
Priority to CN202210818325.5A priority Critical patent/CN116063387B/en
Publication of CN116063387A publication Critical patent/CN116063387A/en
Application granted granted Critical
Publication of CN116063387B publication Critical patent/CN116063387B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a proline protection type anti-enzymolysis antibacterial peptide, a preparation method and application thereof, belonging to the technical field of biology, wherein the sequence of the proline protection type anti-enzymolysis antibacterial peptide is shown as SEQ ID No.1, and a simplification principle is combined with a polypeptide design strategy for reasonably arranging amino acids to avoid protease cleavage sites, so that the anti-enzymolysis peptide with high antibacterial activity, low toxicity and high stability is designed. Through tests, the enzymolysis-resistant antibacterial peptide WPRP5 has obvious inhibition effect on most gram-negative bacteria and gram-positive bacteria tested, and the average antibacterial activity reaches 2.83 mu M. Meanwhile, the hemolytic activity and cytotoxicity are low, and the cell selectivity index is as high as 70.9; in addition, the anti-enzymolysis peptide WPRP5 still maintains higher antibacterial activity in the artificial simulated intestinal juice, the artificial simulated gastric juice and the 10mg/mL chymotrypsin solution; therefore, the anti-enzymolysis antibacterial peptide WPRP5 provided by the invention is an anti-enzymolysis antibacterial peptide with higher clinical application value.

Description

Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a proline protection type enzymolysis-resistant antibacterial peptide, and a preparation method and application thereof.
Background
The problem of resistance to antibiotics abuse has become one of the greatest crisis worldwide. Different from human administration, the feeding antibiotics have the defects of low supervision and general abuse phenomenon, serious exceeding of the residual antibiotics in animals, lowered animal productivity and the like, and restrict the development of animal husbandry. Therefore, the development of novel and green feed antibiotic substitution technology has no doubt great practical significance. The antibacterial peptide is a kind of small molecular polypeptide for resisting the invasion of external microorganisms and eliminating in-vivo mutant cells of animal and plant organisms, and has the advantages of wide antibacterial spectrum, multiple varieties, difficult generation of resistance mutation and the like. It is therefore considered the most powerful alternative to antibiotics. However, natural antimicrobial peptides still have disadvantages such as insufficient potency, high cytotoxicity to mammals, poor stability in salt ion and protease environments, and the like. And as a feed additive, the protease has poor stability and high production cost, which are certainly the biggest barriers preventing the protease from being further popularized and applied. Therefore, the novel synthetic peptide is developed through drug design, and is the best way for solving the application bottleneck of the antibacterial peptide.
In order to solve these problems, covalent bond modification strategies such as cyclization, peptoid and D-type amino acid intercalation are used for improving protease tolerance of artificially synthesized peptides, however, the strategies also greatly increase the synthesis difficulty while improving the protease resistance of the polypeptides, and the peptides cannot be produced in low-cost industrialization through a prokaryotic or eukaryotic expression system. Different from a chemical synthesis strategy for avoiding protease cleavage sites by covalent bond modification, the purpose of improving the resistance of polypeptide protease can be achieved by reasonably arranging natural amino acids to avoid the protease cleavage sites. The cleavage sites of proteases are not identical, but these specific cleavage sites are affected by the amino acid arrangement. For example, trypsin cleaves Arg and Lys preferentially at the P1 position and has a higher specificity for Arg. Cleavage of Arg and Lys by trypsin is hindered when Pro is in the P1 'position, but cleavage of Lys in the P1 position by trypsin is not hindered by Pro in the P1' position when Lys is in the P1 position and Trp is in the P2 position. Similarly, pro at P1', arg at P1 and Met at P2 will not inhibit trypsin cleavage. In addition to the above, the cleavage activity of trypsin on Lys at the P1 position can be blocked in the following cases: asp is at both the P2 and P1' positions; cys at position P2 and Asp at position P1'; his is at the P1' position; cys is at position P2 and Tyr is at position P1'. For Arg at position P1, the amino acid positions that can reduce the cleavage efficiency of trypsin are arranged as follows: arg is at position P2 and His is at position P1'; cys at position P2 and Lys at position P1'; arg is at both the P2 and P1' positions. Chymotrypsin has a high degree of specificity for aromatic amino acids. But Met or Pro in the P1' position prevents chymotrypsin hydrolysis of Trp in the P1 position. In addition, pro at the P1' position also blocks cleavage of Tyr and Phe at the P1 position by chymotrypsin. These rules can be applied reasonably in the modification process of the natural peptide, and can well enhance the protease resistance of the natural peptide. However, according to previous studies, the effectiveness of this strategy is highly dependent on the precise positioning of the amino acids in the sequence, and increasing the resistance of the polypeptide protease while probably destroying the balance of structural parameters of the propeptide, reducing the activity of the propeptide and increasing its cytotoxicity, severely limiting its applicability.
Disclosure of Invention
Based on the problems of the background technology, the invention aims to provide the proline protection type anti-enzymolysis antibacterial peptide WPRP5, which combines a simplification principle with a polypeptide design strategy for reasonably arranging amino acids to avoid protease cleavage sites, so as to design the anti-enzymolysis peptide with high antibacterial activity, low toxicity and high stability, wherein the amino acid sequence of the anti-enzymolysis peptide is shown as SEQ ID No.1, and the molecular formula of the anti-enzymolysis peptide is shown as formula (I):
the invention also aims to provide a preparation method of the proline protection type enzymolysis-resistant antibacterial peptide WPRP5, which comprises the following steps:
(1) The common pepsin, trypsin and chymotrypsin in the gastrointestinal tract of pigs are selected as the target of resistance, trp and Arg are respectively selected as hydrophobic and charged cores according to the simplification principle and protease cleavage site theory, pro is utilized to protect the Trp and Arg, the cleavage effect of the protease chymotrypsin and the pepsin on tryptophan is respectively avoided, and the cleavage effect of the trypsin on arginine is avoidedFor the molecular skeleton model (WPRP) n When n=5, the sequence is shown as SEQ ID No. 1;
(2) Obtaining peptide resin by a solid-phase chemical synthesis method through a polypeptide synthesizer, and cutting the obtained peptide resin by TFA to obtain polypeptide;
(3) After reversed-phase high performance liquid chromatography purification and mass spectrum identification, the preparation of the polypeptide is completed, and then the detection of in-vitro antibacterial activity, hemolytic activity, cytotoxicity, enzymolysis resistance and action mechanism is carried out, so that the polypeptide is named as enzymolysis resistance antibacterial peptide WPRP5.
The invention also aims to provide an application of the proline-protected enzymolysis-resistant antibacterial peptide WPRP5 in preparing a medicament for treating gram-negative bacteria or/and gram-positive bacteria infectious diseases.
The invention has the beneficial effects and advantages that: the enzymolysis-resistant antibacterial peptide WPRP5 has obvious inhibition effect on gram-negative bacteria and gram-positive bacteria such as escherichia coli, salmonella typhimurium, salmonella pullorum, staphylococcus aureus, bacillus subtilis, pseudomonas aeruginosa and the like, and the average antibacterial activity reaches 2.83 mu M. Meanwhile, the hemolytic activity and cytotoxicity are low, and the cell selectivity index is as high as 70.9; in addition, WPRP5 still maintains high antimicrobial activity in artificial simulated intestinal fluid, artificial simulated gastric fluid and 10mg/mL chymotrypsin solution. Therefore, the anti-enzymolysis antibacterial peptide WPRP5 is an anti-enzymolysis antibacterial peptide with higher clinical application value.
Drawings
FIG. 1 is a mass spectrum of an anti-enzymolysis antimicrobial peptide WPRP 5;
FIG. 2 is a chromatogram of the anti-enzymolysis antimicrobial peptide WPRP 5;
FIG. 3 shows the haemolytic activity of the anti-enzymolysis antimicrobial peptide WPRP 5;
FIG. 4 is a cytotoxicity assay of the anti-enzymolysis antimicrobial peptide WPRP 5;
FIG. 5 is a Tricine-SDS-PAGE of the protease treated anti-enzymolysis antimicrobial peptide WPRP 5;
fig. 6 is a TEM image of e.coli 25922 treated with the anti-enzymolysis antimicrobial peptide WPRP5.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but embodiments of the present invention are not limited thereto.
Example 1
Design of anti-enzymolysis antibacterial peptide WPRP 5: trp and Arg are selected as hydrophobic and charged cores respectively according to a simplification principle and a protease cleavage site theory, pro is utilized to protect Trp and Arg, cleavage of tryptophan by chymotrypsin and pepsin and cleavage of arginine by trypsin are avoided respectively, and a molecular skeleton model of the anti-enzymolysis peptide is (WPRP) n (n=1, 2, 3 … …). When the number of the repeated units n is 5, the polypeptide is named as anti-enzymolysis antibacterial peptide WPRP5, and the amino acid sequence is shown in table 1:
TABLE 1 amino acid sequence and major structural parameters of the anti-Enzymolytic antibacterial peptide WPRP5
Molecular structural formula of enzymolysis-resistant antibacterial peptide WPRP5
Example 2
The method for synthesizing the anti-enzymolysis antibacterial peptide WPRP5 by the solid phase chemical synthesis method comprises the following specific steps:
1. the preparation of the polypeptides is carried out one by one from the C end to the N end, and is completed by a polypeptide synthesizer. Fmoc-X (X is the first amino acid at the C-terminal of each antibacterial peptide) is firstly accessed into Wang resin, and then Fmoc groups are removed to obtain X-Wang resin; fmoc-Y-Trt-OH (9-fluorenylmethoxycarbonyl-trimethyl-Y, Y being the second amino acid at the C-terminus of each antimicrobial peptide); the synthesis is sequentially carried out from the C end to the N end according to the procedure until the synthesis is completed, and the side chain protected resin without Fmoc groups is obtained.
2. Adding a cutting reagent into the obtained peptide resin, reacting for 2 hours at 20 ℃ in a dark place, and filtering; washing precipitated TFA (trifluoroacetic acid), mixing the washing solution with the filtrate, concentrating by a rotary evaporator, adding pre-cooled anhydrous diethyl ether with volume about 10 times, precipitating at-20 ℃ for 3 hours, separating out white powder, centrifuging at 2500g for 10min, collecting precipitate, washing the precipitate with anhydrous diethyl ether, and vacuum drying to obtain polypeptide, wherein the cutting reagent is prepared by mixing TFA, water and TIS (triisopropylchlorosilane) according to a mass ratio of 95:2.5:2.5.
3. Performing column balancing with 0.2mol/L sodium sulfate (pH 7.5 is adjusted) for 30min, dissolving polypeptide with 90% acetonitrile water solution, filtering, performing C18 reverse phase normal pressure column, performing gradient elution (eluent is methanol and sodium sulfate water solution mixed according to volume ratio of 30:70-70:30), flowing at 1mL/min, detecting wave at 220nm, collecting main peak, and lyophilizing; further purification using a reverse phase C18 column, eluent a was 0.1% tfa/water; the eluent B is 0.1 percent TFA/acetonitrile solution, the elution concentration is 25 percent B-40 percent B, the elution time is 12min, the flow rate is 1mL/min, and then the main peak is collected and freeze-dried.
4. Identification of antibacterial peptides: the obtained antibacterial peptide is analyzed by electrospray mass spectrometry, and the molecular weight shown in the mass spectrum is basically consistent with the theoretical molecular weight shown in table 1 (see figure 1), and the purity of the antibacterial peptide is more than 95% (see figure 2).
Example 3: and detecting the antibacterial activity, the hemolytic activity, the cytotoxicity, the enzymolysis resistance and the action mechanism of the prepared enzymolysis resistant antibacterial peptide WPRP5 in vitro:
1. determination of antibacterial Activity: the peptides are formulated as a stock solution for use. The minimum inhibitory concentration of the anti-enzymolysis peptide was determined by a micro broth dilution method. Single colonies were inoculated into MHB, cultured at 220rpm at 37℃to logarithmic growth phase, and their concentration was adjusted to OD with MHB 600nm =0.1, finally diluted 1000-fold further with MHB to 0.5-1×10 5 CFU/mL; to line A in a 96-well plate, 95. Mu.L of 0.2% BSA diluent was added, and the remaining wells were added with 50. Mu.L of 0.2% BSA diluent. Add 5. Mu.L of 1.28mM peptide to row A well, mix well, then aspirate 50. Mu.L to row B and push this, dilute the fold to row G, mix well and aspirate 50. Mu.L to discard. Three replicates were set for each assay peptide; 50 mu L of the bacterial liquid is added into a 96-well plate A-In the wells of row G, 50. Mu.L of bacterial liquid is added as positive control in the wells of rows H1-6, 50. Mu.L of fresh MHB culture medium is added as negative control in the wells of rows 7-12, and the mixture is uniformly mixed and then incubated at 37 ℃ for 24 hours. The absorbance was measured at 492nm using an enzyme-labeled instrument to determine the minimum inhibitory concentration. The detection results are shown in Table 2.
TABLE 2 antibacterial Activity of anti-Enzymolytic antibacterial peptide WPRP5
As can be seen from Table 2, the anti-enzymolysis antimicrobial peptide WPRP5 has high-efficiency antibacterial activity on most gram-negative bacteria and gram-positive bacteria tested,
2. determination of haemolytic Activity: collecting 1mL of fresh blood of a human, dissolving the fresh blood into 2mL of PBS solution after anticoagulation of heparin, and collecting red blood cells after centrifugation of 1000g for 5min; after 3 washes with PBS, the suspension was resuspended in 10mL PBS; uniformly mixing 50 mu L of erythrocyte suspension and 50 mu L of anti-enzymolysis antibacterial peptide WPRP5 solution with different concentrations, incubating for 1h at constant temperature in a 37 ℃ incubator, taking out, and centrifuging at 4 ℃ for 5min at 1000 g; taking supernatant, and measuring absorbance value at 570nm by using an enzyme-labeling instrument; each group was averaged and analyzed by comparison. Wherein 50. Mu.L of erythrocytes were added with 50. Mu.L of PBS as a negative control; 50. Mu.L of erythrocytes plus 50. Mu.L of 0.1% Triton x-100 served as positive control. The minimum hemolysis concentration is the concentration of the antimicrobial peptide at which the antimicrobial peptide causes a 10% hemolysis rate. The detection results are shown in FIG. 3 and Table 3.
TABLE 3 calculation of the Selectivity index of the peptide WPRP5
* The selectivity index was calculated with 256. Mu.M at a minimum hemolysis concentration > 128. Mu.M
As can be seen from FIG. 3 and Table 3, the anti-enzymolysis antimicrobial peptide WPRP5 has no obvious hemolytic activity in the detection range.
For analysis of the potential for clinical application of the anti-enzymatic antimicrobial peptide WPRP5, it can be assessed synthetically by the selectivity index (ratio of haemolytic to bacteriostatic concentration). From table 3, it can be seen that the anti-enzymolysis antibacterial peptide WPRP5 has a higher selectivity index, which indicates that the designed anti-enzymolysis antibacterial peptide WPRP5 has the potential of clinically replacing antibiotics.
3. Cytotoxicity assay: resuscitating cells frozen in liquid nitrogen, inoculating into culture medium containing 10% foetal calf serum and 1% double antibody, and inoculating into culture medium containing 5% CO at 37deg.C 2 Subculturing under the condition. The cultured cells were digested with 0.25% pancreatin and adjusted to 2-4X 10 with medium 5 cells/mL. 50. Mu.L of the cell suspension was mixed with 50. Mu.L of the polypeptide at various concentrations in 96-well plates at 37℃in 5% CO 2 Incubation was carried out for 24h, followed by addition of 25. Mu.L MTT (5 mg/mL) per well and incubation was continued for 4h. After the incubation, the supernatant was discarded, the bottom crystals were dissolved in 100. Mu.L of DMSO, and the absorbance value per well was measured at 570nm using an ELISA reader. Medium wells served as blank. The detection results are shown in FIG. 4. As can be seen from fig. 4, the anti-enzymolysis antimicrobial peptide WPRP5 has a certain toxicity to RAW 264.7, and has a low toxicity to the other three test cells, and the cell survival rates of PK-15, HEK 293T and IPEC-J2 are all over 50% after the treatment with the high concentration of the anti-enzymolysis antimicrobial peptide WPRP5.
4. Protease resistance: taking a proper volume of anti-enzymolysis antibacterial peptide WPRP5 mother solution (2.56 mM), vacuum drying, adding an equal volume of simulated human gastrointestinal fluid or 10mg/mL chymotrypsin solution, incubating for 6 hours at 37 ℃, performing ultrasonic vibration, taking out a proper volume of sample, and directly detecting the change of MIC value of the strain to be detected. Heating the rest sample in water bath at 100deg.C for 30min, centrifuging at 13000 Xg for 30min, collecting supernatant, and detecting retention of anti-enzymolysis antibacterial peptide WPRP5 treated by simulated human gastrointestinal fluid and 10mg/mL chymotrypsin solution by SDS-PAGE protein gel. The test results are shown in Table 4 and FIG. 5
TABLE 4 minimum inhibitory concentration of protease-treated peptide WPRP5 against E.coli 25922
a Manual simulation intestinal juice formula: taking 6.8g of monopotassium phosphate, adding 500mL of water to dissolve the monopotassium phosphate, and adjusting the pH value to 6.8 by using 0.1mol/L sodium hydroxide solution; another 10g of pancreatin is taken, dissolved by adding a proper amount of water, the two solutions are mixed, and the mixture is diluted to 1000mL by adding water.
b 10mg/mL
c Manual simulated gastric juice formula: 16.4mL of diluted hydrochloric acid was taken, about 800mL of water and 10g of pepsin were added, and after shaking, the mixture was diluted to 1000mL with water.
As can be seen from Table 4, the antibacterial activity of artificial simulated intestinal juice and 10mg/mL chymotrypsin solution against the enzymolysis antimicrobial peptide WPRP5 is not obviously affected; as can be seen from fig. 5, the protease-treated anti-enzymolysis antimicrobial peptide WPRP5 has a similar protein band to the control group, which demonstrates that the anti-enzymolysis antimicrobial peptide WPRP5 can resist the cleavage of artificial simulated intestinal juice and 10mg/mL chymotrypsin solution. The results show that the anti-enzymolysis antibacterial peptide WPRP5 with brand new design has excellent capability of resisting the hydrolysis of high-concentration protease.
4. Determination of antibacterial action mechanism: and observing the structural change of the thalli after the enzymolysis-resistant antibacterial peptide WPRP5 is treated by a transmission electron microscope. Coli e.coli 25922 single colonies were picked and grown overnight in MHB medium and transferred to new MHB for growth to mid-log phase. The bacterial solution is then centrifuged and resuspended in phosphate buffer to a final concentration of OD 600nm =0.2. And adding the anti-enzymolysis antibacterial peptide WPRP5 parent peptide to make the final concentration of the parent peptide be MIC value. After incubation at room temperature for 2 hours, the supernatant was removed by centrifugation, and the bacterial pellet was fixed with 1% osmium acid fixative for 2 hours. And centrifuging the immobilized thalli, collecting the precipitate, washing the thalli three times by PBS, removing the immobilized liquid, dehydrating the thalli by using 50%, 70%, 90% and 100% ethanol solutions according to a gradient for 8min each time, dehydrating the thalli by using 100% ethanol for 10min each time, replacing the thalli by using a mixed solution of ethanol and acetone (1:1, v/v) for 10min, and replacing the thalli by using pure acetone for 10min. After the replacement, the bacterial precipitate is collected by centrifugation, and is embedded for 30min by adding acetone and resin (1:1, v/v) embedding liquid, and then is changed into 100%Pure resin, embedded overnight. After the sample is formed into blocks, the blocks are sliced by an ultrathin microtome, and the blocks are observed by the microtome after being subjected to double-dyeing by uranium acetate-lead citrate, and the result is shown in figure 6. As shown in fig. 6, compared with the control group, the cell membrane of the escherichia coli treated by the anti-enzymolysis antibacterial peptide WPRP5 is folded, a part of the region forms holes, the cytoplasm flows out, and the cytoplasm wrapped by the cell membrane is scattered around, which indicates that the anti-enzymolysis antibacterial peptide WPRP5 damages the bacterial cell membrane through the action mode of a carpet model and induces bacterial death.
5. The results show that the design strategy of the anti-enzymolysis antibacterial peptide combining the simplification principle and the design strategy of the polypeptide of the protease cleavage site is reasonably arranged and avoided, the designed anti-enzymolysis antibacterial peptide WPRP5 has excellent antibacterial activity and high cell selectivity, and also has extremely strong resistance to artificial simulated intestinal juice and high-concentration chymotrypsin, so that the anti-enzymolysis antibacterial peptide WPRP5 has higher clinical application potential; meanwhile, the membrane-breaking antibacterial mechanism of the anti-enzymolysis antibacterial peptide WPRP5 is similar to a carpet model, so that the possibility of drug resistance of the anti-enzymolysis antibacterial peptide WPRP5 can be effectively reduced, and the anti-enzymolysis antibacterial peptide WPRP5 has higher potential for replacing antibiotics.

Claims (3)

1. A proline protection type enzymolysis resistant antibacterial peptide WPRP5 is characterized in that the amino acid sequence is shown in SEQ ID NO.1, the molecular formula is shown in formula (I), the C terminal adopts amino amidation,
2. the preparation method of the proline-protected enzymolysis-resistant antibacterial peptide WPRP5, which is characterized by comprising the following steps:
(1) The common pepsin, trypsin and chymotrypsin in the gastrointestinal tract of pigs are selected as the target of resistance, trp and Arg are respectively selected as hydrophobic and charged cores according to the simplification principle and the protease cleavage site theory, and Pro is utilized to protect the Trp and Arg, and the Trp and Arg are separatedAvoid the cleavage effect of the protease chymotrypsin and pepsin on tryptophan and the cleavage effect of trypsin on arginine, and the molecular skeleton model is (WPRP) n When n=5, the sequence is shown as SEQ ID No.1, and the C end adopts amino amidation;
(2) Obtaining peptide resin by a solid-phase chemical synthesis method through a polypeptide synthesizer, and cutting the obtained peptide resin by TFA to obtain polypeptide;
(3) After reversed-phase high performance liquid chromatography purification and mass spectrum identification, the preparation of the polypeptide is completed, then the detection of in-vitro antibacterial activity, hemolytic activity, cytotoxicity, enzymolysis resistance and action mechanism is carried out, and finally the polypeptide is named as enzymolysis resistance antibacterial peptide WPRP5.
3. The use of a proline-protected anti-enzymolysis antimicrobial peptide WPRP5 in accordance with claim 1 in the manufacture of a medicament for the treatment of gram negative bacterial or/and gram positive bacterial infectious diseases.
CN202210818325.5A 2022-07-12 2022-07-12 Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof Active CN116063387B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210818325.5A CN116063387B (en) 2022-07-12 2022-07-12 Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210818325.5A CN116063387B (en) 2022-07-12 2022-07-12 Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN116063387A CN116063387A (en) 2023-05-05
CN116063387B true CN116063387B (en) 2023-11-24

Family

ID=86170513

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210818325.5A Active CN116063387B (en) 2022-07-12 2022-07-12 Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN116063387B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017221274A2 (en) * 2017-07-31 2017-12-28 Council Of Scientific & Industrial Research Antimicrobial peptide and its use thereof
CN113549137A (en) * 2021-07-09 2021-10-26 东北农业大学 Proline-rich antibacterial peptide Pyr-2 targeting gram-negative bacteria and preparation method and application thereof
CN113651871A (en) * 2021-08-03 2021-11-16 东北农业大学 Anti-enzymolysis alpha-helical antibacterial peptide bound by all-carbon hydrogen side chain, preparation method and application
CN115785220A (en) * 2022-07-12 2023-03-14 东北农业大学 Tryptophan-enriched antibacterial peptide with high protease stability as well as preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130684A1 (en) * 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017221274A2 (en) * 2017-07-31 2017-12-28 Council Of Scientific & Industrial Research Antimicrobial peptide and its use thereof
CN113549137A (en) * 2021-07-09 2021-10-26 东北农业大学 Proline-rich antibacterial peptide Pyr-2 targeting gram-negative bacteria and preparation method and application thereof
CN113651871A (en) * 2021-08-03 2021-11-16 东北农业大学 Anti-enzymolysis alpha-helical antibacterial peptide bound by all-carbon hydrogen side chain, preparation method and application
CN115785220A (en) * 2022-07-12 2023-03-14 东北农业大学 Tryptophan-enriched antibacterial peptide with high protease stability as well as preparation method and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"细菌生物膜的形成及抗菌肽抗生物膜活性的研究进展";张珊珊 等;《动物营养学报》;第33卷(第12期);第6631-6640页 *
"非完美两亲性α螺旋肽的构效关系及其抗酶解活性的研究";王家俊;《中国博士学位论文全文数据库 (农业科技辑)》(第9期);D050-6 *
Loveland,A.B 等."Chain PR, PR20".《genbank》.2022,ACCESSION 7TOP_PR. *

Also Published As

Publication number Publication date
CN116063387A (en) 2023-05-05

Similar Documents

Publication Publication Date Title
CN111533786B (en) Beta-hairpin antibacterial peptide with tryptophan and arginine cross-chain interaction and preparation method thereof
CN115960261B (en) Tryptophan and phenylalanine cross-chain interaction beta-hairpin antibacterial peptide WFL, and preparation method and application thereof
CN111533789B (en) Tryptophan and lysine chain-crossing interaction beta-hairpin antibacterial peptide and preparation method thereof
CN111423501B (en) Antibacterial peptide derived from scorpion venom as well as preparation method and application thereof
CN115947788B (en) Tryptophan and leucine cross-chain interaction beta-hairpin antibacterial peptide WLF, and preparation method and application thereof
CN115960171A (en) High-stability Trp-pocket cross-chain interactive beta-hairpin antibacterial peptide, and preparation method and application thereof
CN113549137B (en) Proline-rich antibacterial peptide Pyr-2 targeting gram-negative bacteria and preparation method and application thereof
CN117924424B (en) Beta-hairpin antibacterial peptide based on D-type amino acid cross-chain interaction, and preparation method and application thereof
CN113214355B (en) Special antifungal antibacterial peptide GL4W as well as preparation method and application thereof
CN111423493B (en) Palmitic acid anti-enzymolysis antibacterial peptide and preparation method and application thereof
CN114106106A (en) Self-assembled dendritic antibacterial peptide Pal3RP, preparation method thereof, self-assembled nanoparticles thereof and application
CN115785220B (en) Tryptophan-enriched antibacterial peptide with high protease stability and preparation method and application thereof
CN107141338B (en) A kind of antibacterial peptide RW-P and preparation method thereof and application
CN116063387B (en) Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof
CN110294809B (en) Targeting staphylococcus aureus antibacterial peptide S2 and preparation method and application thereof
CN114805495B (en) Enzymolysis-resistant branched antibacterial peptide Pal-CRKP, and preparation method and application thereof
CN114014915A (en) Broad-spectrum antibacterial alpha helical peptide and preparation method and application thereof
CN115819513B (en) Lauric acid modified enzymolysis-resistant peptide and preparation method and application thereof
CN116041476B (en) MALK derived from pig liver to express antibacterial peptide, and preparation method and application thereof
CN116284250B (en) Protease hydrolysis resistant high-stability antibacterial peptide HW, and preparation method and application thereof
CN116143877B (en) Beta hairpin antibacterial peptide based on cation-pi cross-chain interaction, and preparation method and application thereof
CN116063391B (en) Tryptophan and arginine enriched antibacterial peptide WRT6 with high cell selectivity and preparation method and application thereof
CN117924422B (en) Tryptophan and tryptophan cross-chain interaction beta-hairpin antibacterial peptide as well as preparation method and application thereof
CN116478265B (en) Antimicrobial peptide TJH derived from pig liver as well as preparation method and application thereof
CN113683673B (en) Lipopeptide based on melittin and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant